A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

This article examines viral and non-viral vectors in gene therapy, highlighting their mechanisms, advantages, and limitations ...

BioSkryb Genomics, a Durham company focused on single-cell and ultra-low input multiomics, has introduced a new service called ResolveSEQ MRD, which allows more detailed classification and ...

Kyle Registre's childhood dream of becoming a pilot can finally come true now that he says he's been cured of sickle cell complications.

ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical ...

In a landmark achievement for both Uganda and the global medical community, the United States Patent and Trademark Office ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.

Northwestern Medicine investigators have developed a new avenue to reprogram compromised immune cells to act against tumors, ...

Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform. In return, ...

MaxCyte ( NASDAQ: MXCT) Wednesday said that it had entered into a strategic platform license with TG Therapeutics, a fully integrated, commercial-stage, biopharmaceutical company focused on the ...